Millennium Pharmacon International Tbk. vs Tempo Scan Pacific Tbk. — how do they compare? Millennium Pharmacon International Tbk. trades at Rp179 (market cap 230.59B, 19.2K 24h volume), while Tempo Scan Pacific Tbk. trades at Rp2,580 (market cap 11.68T, 429.7K 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 50.7× Millennium Pharmacon International Tbk.'s market cap, and Tempo Scan Pacific Tbk. is more actively traded (429.7K versus 19.2K). Which is the better fit depends on your goals.
| SDPC | TSPC | |
|---|---|---|
Market Cap | 230.59B | 11.68T |
Volume | 19.2K | 429.7K |
Lot | 192 | 4.3K |
Turnover | 3.43M | 1.11B |
Average Price | 178.62 | 2,591.65 |
Value | 3.43M | 1.11B |
Indicative Equilibrium Price | — | 2,580 |
Indicative Equilibrium Volume | — | 100 |
Trailing returns across standard periods
Latest headlines on both assets
PT Millennium Pharmacon International Tbk (the Company) was established on October 20th, 1952 under the name N.V. Perusahaan Dagang SOEDARPO CORPORATION. On July 29th, 1997, the Extraordinary Shareholders meeting held by the Company has approved the sale of assets and of the whole share participation on the Company in PT Praweda Ciptakarsa Informatika and PT Sumber Daya Praweda Informatika. In order to strengthen its equity and settle the foreign currently loan, the Company has conducted its first Right Issue and has submitted the registration statement on May 8th, 2000 to the Capital Advisory Board (BAPEPAM). The Company started its operations on October 20, 1952. The name was changed from previous name PT NVPD Soedarpo Corporation.
Read more on SDPC →PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Read more on TSPC →